Tango Therapeutics to present updated cancer drug combo data at ESMO 2026 in Madrid

Tango Therapeutics announced it will present updated Phase 1/2 study data on its cancer drug vopimetostat combined with daraxonrasib or zoldonrasib at the ESMO Congress 2026 in Madrid. The study targets patients with MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. The presentation is scheduled for October 25, 2026, with abstracts available from October 19. Additionally, the company will host an investor webcast focused on pancreatic cancer data on October 23, 2026. This update highlights Tango's ongoing efforts in precision cancer medicine development.

Tango Therapeutics is set to present new data on its cancer drug combination at the ESMO Congress 2026, highlighting its focus on precision medicine. On Pluang, TNGX shares are stable at USD 22.70 as of Oct 16, 2026 18:11 WIB, with no change in the last day. The stock holds a market cap of $3.83 billion and has traded between $7.50 and $32.90 over the past year.